869901-69-9

• 常用中文名：(6S)-2-[(3-氯-4-氟苯基)甲基]-8-乙基-1,2,6,7,8,9-六氢-10-羟基-N,6-二甲基-1,9-二氧代吡嗪并[1',2':1,5]吡咯并[2,3-d]哒嗪-4-甲酰胺
• 常用英文名：MK-2048
• CAS号：869901-69-9
• 分子式：C₂₁H₂₁ClFN₅O₄
• 分子量：461.874
• 相关类别： 生物化工 抑制剂 微生物学(Microbiology) Integrase 抑制剂
• 发布时间：2017-07-07 22:15:35
• 更新时间：2024-01-13 21:23:52
• MK-2048是HIV整合酶和INR263K的抑制剂,IC50分别为2.6 nM和1.5 nM。

名称

• 中文名: (6S)-2-[(3-氯-4-氟苯基)甲基]-8-乙基-1,2,6,7,8,9-六氢-10-羟基-N,6-二甲基-1,9-二氧代吡嗪并[1',2':1,5]吡咯并[2,3-d]哒嗪-4-甲酰胺
• 英文名: (6S)-2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-6,7-dihydropyrazino[5,6]pyrrolo[1,3-b]pyridazine-4-carboxamide
• 英文别名: (6S)-2-(3-Chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide; 3oyl; ZZX; 3oyn; MK-2048; Pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)-; cc-267

物化性质

• 密度: 1.6±0.1 g/cm3
• 分子式: C₂₁H₂₁ClFN₅O₄
• 分子量: 461.874
• 精确质量: 461.126617
• PSA: 109.46000
• LogP: 1.62
• 外观性状: 粉末
• 折射率: 1.698
• 储存条件: -20℃

生物活性

• 描述: MK-2048是HIV整合酶和INR263K的抑制剂,IC50分别为2.6 nM和1.5 nM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 艾滋病毒整合酶
  信号通路 >> 抗感染 >> HIV
  研究领域 >> 感染
• 参考文献:

  [1]. L. Van Wesenbeeck, E. Rondelez, M. Feyaerts, et al. Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates .Antimicrob. Agents Chem

  [2]. Muhammad Esa Seegulam, Lee Ratner. Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1. Antimicrob. Agents Chemother. 2011, 55 (5): 2011-2017

  [3]. Tamara Bar-Magen1, Richard D. Sloan1, Daniel A. Donahue1, et al. Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor. J. Virol. 2010, 84(18): 9210-9216

  [4]. Laith Q Al-Mawsawi, Rasha I Al-Safi, Nouri Neamati. Anti-infectives Clinical progress of HIV-1 integrase inhibitors. 2008, 13(2): Pages 213-225

  [5]. Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25.